PACS Group (NYSE:PACS) versus BioNexus Gene Lab (NASDAQ:BGLC) Critical Contrast

BioNexus Gene Lab (NASDAQ:BGLC) and PACS Group (NYSE:PACS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares BioNexus Gene Lab and PACS Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-30.70%	-35.54%	-29.08%
PACS Group	N/A	N/A	N/A

Institutional and Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.7% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for BioNexus Gene Lab and PACS Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
PACS Group	1	1	3	0	2.40

PACS Group has a consensus target price of $26.25, indicating a potential upside of 115.16%. Given PACS Group’s stronger consensus rating and higher probable upside, analysts plainly believe PACS Group is more favorable than BioNexus Gene Lab.

Earnings and Valuation

This table compares BioNexus Gene Lab and PACS Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.51 million	0.98	-$1.60 million	($0.57)	-9.11
PACS Group	$3.11 billion	0.60	$112.87 million	$0.31	39.35

PACS Group has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioNexus Gene Lab has a beta of 5.2, indicating that its stock price is 420% more volatile than the S&P 500. Comparatively, PACS Group has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Summary

PACS Group beats BioNexus Gene Lab on 10 of the 14 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.